TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:
CGEN), a leading predictive drug discovery company, today announced
that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of
Compugen, will present a corporate overview and update at the Jefferies
2015 Global Healthcare Conference in London, UK, on Wednesday, November
18, 2015.
About Compugen
Compugen is a leading drug discovery company utilizing its broadly
applicable predictive discovery infrastructure to identify novel drug
targets and develop first-in-class biologics. The Company’s current
pipeline primary focus is on immune checkpoint target candidates
discovered by the Company, potentially providing the basis for a next
wave of therapeutics for cancer immunotherapy. Compugen’s business model
is based on selectively entering into collaborations for its novel
targets and drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Tel Aviv, Israel, with R&D facilities in Tel Aviv and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company’s novel target candidates. For additional information, please
visit Compugen's corporate website at www.cgen.com.